- The trend backdrop is active with a 48-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
JNJ
GER
Week ended 07 Aug 2026
Weekly Investor Report
Johnson & Johnson · Healthcare · Drug Manufacturers - General
Latest close
221.9 EUR
-1.0%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is 8.1% above the Trend Line and sits at 80.1% of its 52-week range. The latest completed week returned -1.0%, after a -1.9% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers. The latest news-sentiment score is 65/100.
Setup score
71
out of 100
Latest Close
221.9 EUR
7 Aug 2026
1W Return
-1.0%
latest completed week
4W Return
-1.9%
short-term follow-through
12W Return
13.7%
quarterly tape
Trend Breadth
92.3%
48 of 52 weeks active
Volume Ratio
1.7x
vs 13-week average
- 2 reversal markers appear in the recent smart-money tape.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-1.0%
Latest completed week; four-week move -1.9%.
Indicator stack
96/100
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
65/100
32 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 8.1% above the Trend Line and sits at 80.1% of its 52-week range. The latest completed week returned -1.0%, after a -1.9% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.7x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.7512-week average 0.65
12-week confirmation
Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure5/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.75Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers
No recent accumulation markers. 2 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -1.9% over four weeks, 13.7% over 12 weeks, and 53.8% over one year. The current trend has remained active for 48 consecutive weeks.
Performance by holding period
Active trend streak48 weeks
Active weeks in one year48
Trend breadth92.3%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.97Latest activity-pressure read.
Pressure change640.8%Four-week change in activity pressure.
Leadership9.89Latest relative-leadership reading.
RS change-53.4%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 91%
Model confidence 85%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength47/100Blend of value, momentum, and quality. Underlying universe rank 54; rank 1 is best.
Value13/100Relative valuation strength. Underlying universe rank 88; rank 1 is best.
Quality81/100Profitability and accounting quality. Underlying universe rank 20; rank 1 is best.
Momentum86/100Medium-term price momentum. Underlying universe rank 15; rank 1 is best.
Growth91/100Revenue and earnings growth. Underlying universe rank 10; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 25.4x Price divided by trailing earnings.
- Price / sales
- 5.5x Market value relative to trailing revenue.
- EV / EBITDA
- 16.8x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 3.1% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 67.8% Gross profit retained from each unit of revenue.
- Operating margin
- 26.8% Operating profit retained from revenue.
- Free-cash-flow margin
- 18.1% Free cash flow generated from revenue.
- Return on invested capital
- 16.9% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 6.0% Latest one-year revenue growth.
- EPS growth
- 90.5% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- 6.9% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 3/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 2.0% Cash dividends relative to market value.
- Buyback yield
- 1.5% Net share repurchases relative to market value.
- Shareholder yield
- 3.5% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 1.0x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment65/100
Weighted news tone is positive across 32 relevant articles.
13 positive · 18 neutral · 1 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-8.1%Distance below the 52-week high.
13-week volatility4.2%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher13 of 2613 weeks finished lower.
Best week+11.9%Week of 26 Jun.
Worst week-4.1%Week of 20 Mar.
Latest week-1.0%Week of 7 Aug.
Shape of recent returns
Strong gains3
Modest gains10
Flat weeks0
Modest losses11
Sharp losses2
Recent vol4.2%13-week weekly-return volatility.
Base vol3.2%52-week weekly-return volatility.
Up/down split28/24Count of positive and negative weeks in the 52-week window.
Average skew3.2% / -1.8%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorDE Healthcare
4-week rank47 / 78
Group average1.4%
Trend breadth39.7%
Trend39.7%active weekly trend signals
MD69.2%positive activity pressure
RS34.6%positive relative leadership
Four-week leaders
IndustryDE Drug Manufacturers - General
4-week rank10 / 12
Group average2.5%
Trend breadth58.3%
Trend58.3%active weekly trend signals
MD83.3%positive activity pressure
RS66.7%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape75/100
Trend, activity pressure, participation, and risk combine to a 75/100 tape read.
Indicator analysis71/100Latest 12-week confirmation: trend 12/12, activity pressure 5/12, relative leadership 12/12.
Activity pressure 0.75; 2 reversal markers Factors55/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 24 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment65/100Weighted news tone is positive across 32 relevant articles.
Johnson & Johnson Nearing 52-Week High: Buy, Sell or Hold? Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 221.9 EUR | -1.0% | 205.3 EUR | 152.3 EUR | 0.97 | 9.89 | 12.5K | On |
| 31 Jul 2026 | 224.1 EUR | -2.9% | 203.7 EUR | 151.8 EUR | 1.02 | 14.67 | 17.4K | On |
| 24 Jul 2026 | 230.7 EUR | 3.6% | 202.0 EUR | 151.3 EUR | 0.86 | 21.40 | 7.4K | On |
| 17 Jul 2026 | 222.7 EUR | -1.5% | 200.1 EUR | 150.7 EUR | 0.65 | 19.50 | 14.1K | On |
| 10 Jul 2026 | 226.1 EUR | -1.6% | 198.5 EUR | 150.2 EUR | 0.13 | 21.24 | 9.7K | On |
| 3 Jul 2026 | 229.9 EUR | 3.3% | 196.9 EUR | 149.5 EUR | -0.28 | 20.97 | 950 | On |
| 26 Jun 2026 | 222.4 EUR | 11.9% | 195.0 EUR | 148.9 EUR | -0.63 | 23.43 | 2.4K | On |
| 19 Jun 2026 | 198.8 EUR | -4.1% | 193.4 EUR | 148.4 EUR | -0.92 | 10.01 | 914 | On |
| 12 Jun 2026 | 207.1 EUR | 2.3% | 192.6 EUR | 148.0 EUR | -0.91 | 17.08 | 2.0K | On |
| 5 Jun 2026 | 202.4 EUR | 4.0% | 191.2 EUR | 147.5 EUR | -1.00 | 14.71 | 1.7K | On |
| 29 May 2026 | 194.7 EUR | -3.0% | 189.7 EUR | 147.1 EUR | -1.06 | 9.60 | 8.5K | On |
| 22 May 2026 | 200.8 EUR | 2.9% | 188.6 EUR | 146.7 EUR | -1.10 | 14.73 | 7.1K | On |
| 15 May 2026 | 195.2 EUR | 4.4% | 187.2 EUR | 146.2 EUR | -1.14 | 16.71 | 10.7K | On |
| 8 May 2026 | 186.9 EUR | -3.9% | 186.1 EUR | 145.8 EUR | -1.07 | 10.82 | 9.7K | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.